Yu Hongwei, Fischer Gregory, Ebert Allison D, Wu Hsiang-En, Bai Xiaowen, Hogan Quinn H
Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Mol Pain. 2015 Feb 12;11:5. doi: 10.1186/s12990-015-0002-9.
BACKGROUND: Cell-based therapy may hold promise for treatment of chronic pain. Mesenchymal stem cells (MSCs) are readily available and robust, and their secretion of therapeutic peptides can be enhanced by genetically engineering. We explored the analgesic potential of transplanting bone marrow-derived MSCs that have been transduced with lentivectors. To optimize efficacy and safety, primary sensory neurons were targeted by MSC injection into the dorsal root ganglia (DRGs). RESULTS: MSCs were transduced using lentivectors to express enhanced green fluorescent protein (EGFP) or to co-express the analgesic peptide glial cell line-derived neurotrophic factor (GDNF) and EGFP by a viral 2A bicistronic transgene cassette. Engineered MSCs were injected into the 4(th) lumbar (L4) and L5 DRGs of adult allogeneic rats to evaluate survival in the DRGs. MSCs were detected by immunofluorescence staining up to 2-3 weeks after injection, distributed in the extracellular matrix space without disrupting satellite glial cell apposition to sensory neurons, suggesting well-tolerated integration of engrafted MSCs into DRG tissue. To examine their potential for inhibiting development of neuropathic pain, MSCs were injected into the L4 and L5 DRGs ipsilateral to a spinal nerve ligation injury. Animals injected with GDNF-engineered MSCs showed moderate but significant reduction in mechanical allodynia and hyperalgesia compared to controls implanted with MSCs expressing EGFP alone. We also observed diminished long-term survival of allografted MSCs at 3 weeks, and the development of a highly-proliferating population of MSCs in 12% of DRGs after transplantation. CONCLUSIONS: These data indicate that genetically modified MSCs secreting analgesic peptides could potentially be developed as a novel DRG-targeted cell therapy for treating neuropathic pain. However, further work is needed to address the challenges of MSC survival and excess proliferation, possibly with trials of autologous MSCs, evaluation of clonally selected populations of MSCs, and investigation of regulation of MSC proliferation.
背景:基于细胞的疗法可能为慢性疼痛的治疗带来希望。间充质干细胞(MSCs)易于获取且生命力强,通过基因工程可增强其治疗性肽的分泌。我们探索了移植经慢病毒载体转导的骨髓源性MSCs的镇痛潜力。为了优化疗效和安全性,通过将MSCs注射到背根神经节(DRGs)中来靶向初级感觉神经元。 结果:使用慢病毒载体转导MSCs,使其表达增强型绿色荧光蛋白(EGFP),或通过病毒2A双顺反子转基因盒共表达镇痛肽胶质细胞源性神经营养因子(GDNF)和EGFP。将工程化的MSCs注射到成年同种异体大鼠的第4腰椎(L4)和L5 DRGs中,以评估其在DRGs中的存活情况。注射后2至3周通过免疫荧光染色检测到MSCs,它们分布在细胞外基质空间,未破坏卫星胶质细胞与感觉神经元的贴附,这表明移植的MSCs能很好地整合到DRG组织中。为了检验它们抑制神经性疼痛发展的潜力,将MSCs注射到脊髓神经结扎损伤同侧的L4和L5 DRGs中。与仅植入表达EGFP的MSCs的对照组相比,注射GDNF工程化MSCs的动物在机械性异常性疼痛和痛觉过敏方面有中度但显著的减轻。我们还观察到移植后3周异体移植MSCs的长期存活率降低,并且在12%的DRGs中出现了高度增殖的MSCs群体。 结论:这些数据表明,分泌镇痛肽的基因修饰MSCs有可能被开发成为一种新型的靶向DRG的细胞疗法来治疗神经性疼痛。然而,需要进一步开展工作来应对MSCs存活和过度增殖的挑战,可能需要进行自体MSCs试验、评估克隆选择的MSCs群体以及研究MSCs增殖的调控。
J Clin Invest. 2015-8-3
Front Cell Dev Biol. 2025-2-21
Stem Cell Res Ther. 2024-7-18
Mater Today Bio. 2023-5-19
Front Mol Neurosci. 2023-2-27
J Neuroimmune Pharmacol. 2021-9
Stem Cells Int. 2020-12-28
Front Immunol. 2014-5-19
Nat Biotechnol. 2014-3
Proc Natl Acad Sci U S A. 2014-2-11
Int J Mol Sci. 2014-1-23